Complications: Tracking down the data on oseltamivir

BMJ

Volumn 339, Issue , 2009, Pages

  Cohen, Deborah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR;

ARTICLE; HUMAN; INFLUENZA; LITERATURE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; STATISTICAL ANALYSIS;

ANTIVIRAL AGENTS; DATA INTERPRETATION, STATISTICAL; HUMANS; INFLUENZA, HUMAN; OSELTAMIVIR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT DISEASES; REVIEW LITERATURE AS TOPIC;

EID: 85007750018     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.b5387     Document Type: Article

References (21)

1. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163: 1667–1672.
2. Smith J, on behalf of Roche. Point-by-point response from Roche to BMJ questions. BMJ 2009; 339: b5374.
3. Roche. Roche announces further progress in Tamiflu. Media release, Basel, 7 November 2005. www.roche.com/med-cor-2005–11–07.
4. Department of Health. Use of antiviral drugs in an influenza pandemic: scientific evidence base. www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_077274.pdf.
5. Donaldson L. A pandemic on the horizon. J R Soc Med 2006; 99: 222225
6. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 1016–1024.
7. Hayden FG. Pandemic influenza: is an antiviral response realistic? Pediatr Infect Dis J 2004; 23(11 Suppl):S262–9.
8. Hama R. Discussion of the causal relationship between oseltamivir phosphate (Tamiflu), and sudden death and death from abnormal behaviour [presentation at a session of Japanese Society for Pediatric Infectious Diseases in Tsu, Mie Prefecture, 12 November 2005. www.npojip.org/sokuho/051112.html (in Japanese), www.npojip.org/english/no59.html (in English)]
9. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367: 303–313.
10. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000;355:1845–1850.
11. Li L, Cai B, Wang M, Zhu Y. A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. Chin Med J 2003; 116: 44–48.
12. Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I. [Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza–placebo-controlled double-blind multicenter phase III trial] Kansenshogaku Zasshi 2000; 74: 1044–1061.
13. Shun-Shin M, Thompson M, Heneghan C, Perera R, Harnden A, Mant D. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ 2009; 339: b3172.
14. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009; 339: b5106.
15. Hoffman-La Roche. Product label. Tamiflu (oseltamivir phosphate) capsules and for oral suspension. 25 September 2008. www.accessdata.fda.gov/drugsatfda_docs/label/2008/021087s047,%20021246s033lbl.pdf.
16. Freemantle N, Calvert M. What can we learn from observational studies of oseltamivir to treat influenza in healthy adults? BMJ 2009; 339: b5248.
17. Smith J, on behalf of Roche. Roche replies to the authors of the Cochrane Review on oseltamivir. BMJ 2009; 339: b5364.
18. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935
19. Treanor JJ. Reduction in the symptoms and complications of influenza A and B with oseltamivir. Presented at the 38th Annual Meeting of the Infectious Disease Society of America. New Orleans, 7–10 September 2000. Abstract 611.
20. Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, et al. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009; 339: b4330.
21. Cite this as: BMJ 2009;339:b5387